menu
    • menu
    [{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cipla Medpro","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ Cipla Medpro","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Cipla Medpro"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Corium","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Serdexmethylphenidate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"KemPharm","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"KemPharm \/ Gurnet Point Capital ","highestDevelopmentStatusID":"12","companyTruncated":"KemPharm \/ Gurnet Point Capital "},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aspargo Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aspargo Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2C receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes Plc \/ Not Applicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2C receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes Plc \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Moksha8","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ Moksha8","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Moksha8"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Neurotrope","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Avanafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Neurotrope","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pharmaceuticals \/ Neurotrope"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2C receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes Plc \/ Not Applicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Alvogen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ Alvogen Korea","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Alvogen Korea"},{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Camurus \/ Not Applicable"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Methylphenidate Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Ironshore Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended Release Capsule","sponsorNew":"Ironshore Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Ironshore Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim ImmunoTech \/ Not Applicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim ImmunoTech \/ Not Applicable"},{"orgOrder":0,"company":"Tanner Pharma","sponsor":"Tasmanian Alkaloids Pty Ltd","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Clozapine","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tanner Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Tanner Pharma \/ Tasman Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Tanner Pharma \/ Tasman Pharma"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Indegene Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subdermal Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ Indegene Inc","highestDevelopmentStatusID":"12","companyTruncated":"Titan Pharmaceuticals Inc \/ Indegene Inc"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"KYE Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Tris Pharma Inc \/ KYE Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharma Inc \/ KYE Pharmaceuticals"},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"KemPharm \/ Not Applicable"},{"orgOrder":0,"company":"Indoco Remedies Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Olanzapine","moa":"5-HT2C receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indoco Remedies Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Indoco Remedies Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indoco Remedies Limited \/ Not Applicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu\/kappa\/delta opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emergent BioSolutions \/ Not Applicable"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Molteni Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Implant","sponsorNew":"Accord healthcare \/ Molteni Farmaceutici","highestDevelopmentStatusID":"12","companyTruncated":"Accord healthcare \/ Molteni Farmaceutici"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"CAP ALTER PHARMA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ CAP ALTER PHARMA","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ CAP ALTER PHARMA"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Aripiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Methylphenidate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Moksha8 Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Moksha8 Pharmaceuticals \/ Janssen","highestDevelopmentStatusID":"12","companyTruncated":"Moksha8 Pharmaceuticals \/ Janssen"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim ImmunoTech \/ Not Applicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Farmalider SA","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aspargo Laboratories \/ Farmalider","highestDevelopmentStatusID":"12","companyTruncated":"Aspargo Laboratories \/ Farmalider"},{"orgOrder":0,"company":"Federal Emergency Management Agency","sponsor":"US WorldMeds","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Federal Emergency Management Agency","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Federal Emergency Management Agency \/ US WorldMeds","highestDevelopmentStatusID":"12","companyTruncated":"Federal Emergency Management Agency \/ US WorldMeds"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharma Inc \/ Not Applicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"KemPharm \/ Not Applicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim ImmunoTech \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual thin film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Tris Pharma Inc \/ Medison Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharma Inc \/ Medison Pharma"},{"orgOrder":0,"company":"Angelini Pharma","sponsor":"Sunovion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lurasidone Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Angelini Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Angelini Pharma \/ Sunovion Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Angelini Pharma \/ Sunovion Pharmaceutical"},{"orgOrder":0,"company":"HLS Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Risperidone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"HLS Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended-release Injectable Suspension","sponsorNew":"HLS Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"HLS Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Distriphil","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Quetiapine Hemifumarate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Luye Pharma \/ Distriphil","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Distriphil"},{"orgOrder":0,"company":"Regent Pacific","sponsor":"Wanbang Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"HONG KONG","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunits","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Regent Pacific","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Cutaneous spray","sponsorNew":"Regent Pacific \/ Wanbang Pharmaceutical Marketing and Distribution","highestDevelopmentStatusID":"12","companyTruncated":"Regent Pacific \/ Wanbang Pharmaceutical Marketing and Distribution"},{"orgOrder":0,"company":"Orexo","sponsor":"Accord healthcare","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Buprenorphine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Orexo \/ Accord","highestDevelopmentStatusID":"12","companyTruncated":"Orexo \/ Accord"},{"orgOrder":0,"company":"Neos Therapeutics","sponsor":"Aytu BioScience","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Merger","leadProduct":"Methylphenidate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Neos Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Neos Therapeutics \/ Aytu BioScience","highestDevelopmentStatusID":"12","companyTruncated":"Neos Therapeutics \/ Aytu BioScience"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Asenapine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Asenapine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal patch","sponsorNew":"Noven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Noven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Orexo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Orexo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Orexo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Orexo \/ Not Applicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim ImmunoTech \/ Not Applicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended-release tablet","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharma Inc \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nortriptyline","moa":"Sodium-dependent noradrenaline transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Numinus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Numinus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Numinus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Numinus \/ Not Applicable"},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"The Queen's University of Belfast","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"PharmaTher \/ The Queen's University of Belfast","highestDevelopmentStatusID":"12","companyTruncated":"PharmaTher \/ The Queen's University of Belfast"},{"orgOrder":0,"company":"Futura Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"MED3000","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Futura Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Futura Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Futura Medical \/ Not Applicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Serdexmethylphenidate","moa":"Dopamine\/Norepinephrine level","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"KemPharm","amount2":0.58999999999999997,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.58999999999999997,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Gurnet Point Capital","highestDevelopmentStatusID":"12","companyTruncated":"KemPharm \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Viloxazine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Supernus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Opioid receptors","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Olanzapine","moa":"Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes Plc \/ Not Applicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbeck AS \/ Not Applicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Camurus \/ Not Applicable"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin reuptake","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbeck AS \/ Not Applicable"},{"orgOrder":0,"company":"IQVIA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine\/Norepinephrine level","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IQVIA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IQVIA \/ Not Applicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Olanzapine","moa":"Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes Plc \/ Not Applicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Commave Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Serdexmethylphenidate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"KemPharm","amount2":0.58999999999999997,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.58999999999999997,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Commave Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"KemPharm \/ Commave Therapeutics"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Qilu Pharmaceutical","sponsor":"ECI Pharmaceuticals LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Qilu Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Qilu Pharmaceutical \/ ECI Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Qilu Pharmaceutical \/ ECI Pharmaceuticals"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Purdue Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Purdue Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Braeburn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braeburn \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Amitriptyline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem Laboratories Limited \/ Not Applicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naltrexone","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes Plc \/ Not Applicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Olanzapine","moa":"Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes Plc \/ Not Applicable"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Avanafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Adlon Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Methylphenidate Hydrochloride","moa":"Sodium-dependent dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Adlon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adlon Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adlon Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CV Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"CV Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"CV Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CV Science \/ Not Applicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"National Institutes of Health \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"National Institutes of Health \/ Not Applicable"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Avanafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Clomipramine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Orally-disintegrating Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Chlordiazepoxide","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim ImmunoTech \/ Not Applicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Risperidone","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"MedinCell \/ Teva","highestDevelopmentStatusID":"12","companyTruncated":"MedinCell \/ Teva"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Corium","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Dexmethylphenidate","moa":"Dopamine\/Norepinephrine level","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corium \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ Hercules Capital"},{"orgOrder":0,"company":"Par Pharmaceutical","sponsor":"Endo International","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"ACh receptor alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Par Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Par Pharmaceutical \/ Endo International","highestDevelopmentStatusID":"12","companyTruncated":"Par Pharmaceutical \/ Endo International"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Braxia Scientific \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braxia Scientific \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Katalyst Securities","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Avanafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Katalyst Securities","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pharmaceuticals \/ Katalyst Securities"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"KemPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine\/Norepinephrine level","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"KemPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"KemPharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"KemPharm \/ Not Applicable"},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine\/Norepinephrine level","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Hims & Hers Health, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Avanafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Hims & Hers Health, Inc.","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pharmaceuticals \/ Hims & Hers Health, Inc."},{"orgOrder":0,"company":"MedinCell","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Risperidone","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"MedinCell","amount2":0.12,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.12,"dosageForm":"Subcutaneous Injection","sponsorNew":"MedinCell \/ Teva Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"MedinCell \/ Teva Pharmaceuticals"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA 3A","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Pasithea Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pasithea Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Katalyst Securities LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Public Offering","leadProduct":"Avanafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Katalyst Securities LLC","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pharmaceuticals \/ Katalyst Securities LLC"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Adamis Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Venlafaxine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended Release Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Yiling Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Traditional Chinese Medicine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Yiling Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Yiling Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Yiling Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sandoz B2B","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Sandoz B2B \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sandoz B2B \/ Not Applicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin reputake","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Avanafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Indivior","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptors","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptors","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"H. Lundbeck A\/S","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Holdings \/ H. Lundbeck A\/S","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Holdings \/ H. Lundbeck A\/S"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptors","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Purdue Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Exhale Wellness","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Exhale Wellness","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Gummies","sponsorNew":"Exhale Wellness \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exhale Wellness \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha 2","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Thin Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"Selective serotonin","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sprout Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Flibanserin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sprout Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Sprout Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sprout Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Purdue Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Purdue Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Sun Pharmaceutical Industries Limited","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Vortioxetine Hydrobromide","moa":"5-HT","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sun Pharmaceutical Industries Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Sun Pharmaceutical Industries Limited \/ H. Lundbeck","highestDevelopmentStatusID":"12","companyTruncated":"Sun Pharmaceutical Industries Limited \/ H. Lundbeck"},{"orgOrder":0,"company":"Corium","sponsor":"Gurnet Point Capital","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Corium \/ Gurnet Point Capital","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ Gurnet Point Capital"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"US WorldMeds","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Adamis Pharmaceuticals \/ US WorldMeds","highestDevelopmentStatusID":"12","companyTruncated":"Adamis Pharmaceuticals \/ US WorldMeds"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Braxia Scientific \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braxia Scientific \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Olanzapine","moa":"Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes Plc \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Oaktree Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.13,"dosageForm":"Sublingual Film","sponsorNew":"BioXcel Therapeutics \/ Oaktree Capital","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Therapeutics \/ Oaktree Capital"},{"orgOrder":0,"company":"Petros Pharmaceuticals","sponsor":"Endo Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Avanafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Petros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Petros Pharmaceuticals \/ Auxilium Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Petros Pharmaceuticals \/ Auxilium Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Laboratoires DELBERT","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Lithium Carbonate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Laboratoires DELBERT","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Laboratoires DELBERT"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Viloxazine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Supernus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Rubio Laboratories","sponsor":"Aspargo Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ARGENTINA","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Rubio Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Rubio Laboratories \/ Aspargo Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Rubio Laboratories \/ Aspargo Laboratories"},{"orgOrder":0,"company":"InfectoPharm Drugs and Consilium","sponsor":"Societal CDMO","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"InfectoPharm Drugs and Consilium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended-release Capsule","sponsorNew":"InfectoPharm Drugs and Consilium \/ Societal","highestDevelopmentStatusID":"12","companyTruncated":"InfectoPharm Drugs and Consilium \/ Societal"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"Selective serotonin","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"Assia Chemical Industries Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Risperidone","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended-release Suspension for Injection","sponsorNew":"MedinCell \/ TEVA","highestDevelopmentStatusID":"12","companyTruncated":"MedinCell \/ TEVA"},{"orgOrder":0,"company":"Almirall","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Diazepam","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film-coated Tablet","sponsorNew":"Almirall \/ Neuraxpharm","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/ Neuraxpharm"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Braxia Scientific \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braxia Scientific \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cariprazine Hydrochloride","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Fluphenazine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Methylphenidate Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Nicotine","moa":"ACh receptor alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"Mu opoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Aripiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution For Injection In Pre-Filled Syringe","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Vanquish Group","sponsor":"Aspargo Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"MEXICO","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Vanquish Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Vanquish Group \/ Aspargo Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"Vanquish Group \/ Aspargo Laboratories"},{"orgOrder":0,"company":"Canntab Therapeutics","sponsor":"MediPharm Labs","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Canntab Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Canntab Therapeutics \/ MediPharm Labs","highestDevelopmentStatusID":"12","companyTruncated":"Canntab Therapeutics \/ MediPharm Labs"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Purdue Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Purdue Pharma \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Lundbeck","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Lundbeck"},{"orgOrder":0,"company":"Sanofi","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Levomepromazine Maleate","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Neuraxpharm","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Neuraxpharm"},{"orgOrder":0,"company":"Brand Institute","sponsor":"Osmotica Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Methylphenidate Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Brand Institute","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Brand Institute \/ Osmotica Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Brand Institute \/ Osmotica Pharmaceuticals"},{"orgOrder":0,"company":"Avicanna","sponsor":"Ei.Ventures","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Avicanna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Avicanna \/ Ei.Ventures","highestDevelopmentStatusID":"12","companyTruncated":"Avicanna \/ Ei.Ventures"},{"orgOrder":0,"company":"MKS Enterprise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Caviar","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"MKS Enterprise","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Sachet\n","sponsorNew":"MKS Enterprise \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MKS Enterprise \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Lotus Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Eli Lilly","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Lotus Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Lotus Pharmaceuticals"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"InfectoPharm Drugs and Consilium","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Societal CDMO \/ InfectoPharm","highestDevelopmentStatusID":"12","companyTruncated":"Societal CDMO \/ InfectoPharm"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharma Inc \/ Not Applicable"},{"orgOrder":0,"company":"Exhale Wellness","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Exhale Wellness","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Gummies","sponsorNew":"Exhale Wellness \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Exhale Wellness \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Lundbeck","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Lundbeck"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Nalmefene Hydrochloride","moa":"Opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Intellipharmaceutics Corporation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Desvenlafaxine Succinate","moa":"SNRI","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Taro Pharmaceutical Industries \/ Intellipharmaceutics","highestDevelopmentStatusID":"12","companyTruncated":"Taro Pharmaceutical Industries \/ Intellipharmaceutics"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Methylphenidate Hydrochloride","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Chewable","sponsorNew":"Tris Pharma Inc \/ Teva","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharma Inc \/ Teva"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dextromethorphan Hydrobromide","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Axsome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Extended Release Subcutaneous Injection","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Tilray","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Tilray \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tilray \/ Not Applicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Biophore India Pharmaceuticals Pvt Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Prochlorperazine Maleate","moa":"Dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ANI Pharmaceuticals Inc \/ Biophore India Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharmaceuticals Inc \/ Biophore India Pharmaceuticals"},{"orgOrder":0,"company":"22nd Century Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nicotine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"22nd Century Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"22nd Century Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"22nd Century Group \/ Not Applicable"},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Aripiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution For Injection In Pre-Filled Syringe","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Ketamine Wellness Center","sponsor":"Delic Corp","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Ketamine Wellness Center","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Ketamine Wellness Center \/ Delic Corp","highestDevelopmentStatusID":"12","companyTruncated":"Ketamine Wellness Center \/ Delic Corp"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Taiba Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aspargo Laboratories \/ Taiba Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Aspargo Laboratories \/ Taiba Healthcare"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Lundbeck","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Lundbeck"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Amphetamine","moa":"CNS","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Aytu BioPharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aytu BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Amphetamine","moa":"VMAT","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Noven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Noven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Aim ImmunoTech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aim ImmunoTech \/ Not Applicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Noven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Noven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"GABA A receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"MedinCell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Risperidone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"MedinCell","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MedinCell \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MedinCell \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Nalmefene Hydrochloride","moa":"CB receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.20999999999999999,"dosageForm":"Spray","sponsorNew":"Indivior \/ Indivior","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Indivior"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"MedinCell","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Risperidone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"MedinCell","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.040000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"MedinCell \/ European Investment Bank","highestDevelopmentStatusID":"12","companyTruncated":"MedinCell \/ European Investment Bank"},{"orgOrder":0,"company":"Bausch Health","sponsor":"MedQu\u00edmica Ind\u00fastria Farmac\u00eautica","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Chlordiazepoxide","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bausch Health \/ MedQu\u00edmica Ind\u00fastria Farmac\u00eautica","highestDevelopmentStatusID":"12","companyTruncated":"Bausch Health \/ MedQu\u00edmica Ind\u00fastria Farmac\u00eautica"},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Padagis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Padagis \/ Not Applicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Fluoxetine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"ANI Pharmaceuticals Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ANI Pharmaceuticals Inc \/ Not Applicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Pediatrix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Pediatrix Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharma Inc \/ Pediatrix Therapeutics"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Essential Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Haloperidol Decanoate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Essential Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Essential Pharma"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emergent BioSolutions \/ Not Applicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Dextromethorphan Hydrobromide","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Axsome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Braeburn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Braeburn \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braeburn \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cariprazine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Braeburn","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Braeburn \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braeburn \/ Not Applicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Noven Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Noven Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Levomilnacipran","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Risperidone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Luye Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emergent BioSolutions \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fluoxetine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Marksans Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marksans Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Marksans Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aspargo Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aspargo Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Psilocybine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PharmAla Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmAla Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Biogen","highestDevelopmentStatusID":"12","companyTruncated":"Sage Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Hims","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Hims","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hims \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hims \/ Not Applicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emergent BioSolutions \/ Not Applicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Loxapine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film","sponsorNew":"IntelGenx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"IntelGenx \/ Not Applicable"},{"orgOrder":0,"company":"Accord healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lurasidone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Accord healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Accord healthcare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Accord healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Nalmefene Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.20999999999999999,"dosageForm":"Spray","sponsorNew":"Indivior \/ Indivior","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Indivior"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Cediprof","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Dextroamphetamine Saccharate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Cediprof","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Cediprof"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alembic Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Pharmaceuticals Limited \/ Not Applicable"},{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Amphastar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amphastar Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Olanzapine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lurasidone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo Pharma Limited \/ Not Applicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Purdue Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Harm Reduction Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Spray","sponsorNew":"Harm Reduction Therapeutics \/ Purdue Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Harm Reduction Therapeutics \/ Purdue Pharma"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Prochlorperazine Maleate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Aurobindo Pharma Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aurobindo Pharma Limited \/ Not Applicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Teva Pharmaceutical Industries \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Doxepin Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Doxepin Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emergent BioSolutions \/ Not Applicable"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fluphenazine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Upsher-Smith Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Upsher-Smith Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Aripiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Pocket Naloxone","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Pocket Naloxone","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Swab","sponsorNew":"Pocket Naloxone \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pocket Naloxone \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Cheplapharm Arzneimittel Gmbh","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Olanzapine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Cheplapharm Arzneimittel Gmbh","amount2":0.82999999999999996,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.82999999999999996,"dosageForm":"Tablet","sponsorNew":"Cheplapharm Arzneimittel Gmbh \/ Undisclosed","highestDevelopmentStatusID":"12","companyTruncated":"Cheplapharm Arzneimittel Gmbh \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Aripiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"H. Lundbeck AS \/ Otsuka Holdings","highestDevelopmentStatusID":"12","companyTruncated":"H. Lundbeck AS \/ Otsuka Holdings"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Risperidone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"12","companyTruncated":"Teva Pharmaceutical Industries \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Sanofi","sponsor":"Neuraxpharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Levomepromazine Maleate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Neuraxpharm","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Neuraxpharm"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nicotine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"Perrigo Company plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Perrigo Company plc \/ Not Applicable"},{"orgOrder":0,"company":"Corium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Serdexmethylphenidate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Corium","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corium \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Corium \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Camurus \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Camurus \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Nalmefene Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Not Applicable"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Diazepam","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Fresenius Kabi AB Brunna \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AB Brunna \/ Not Applicable"},{"orgOrder":0,"company":"Futura Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"MED3000","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Futura Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"Futura Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Futura Medical \/ Not Applicable"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Alprostadil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"UCB Pharma S.A \/ Advanz Pharma","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Advanz Pharma"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Aripiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem Laboratories Limited \/ Not Applicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"CSPC Pharmaceutical Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Paliperidone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"CSPC Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"CSPC Pharmaceutical Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSPC Pharmaceutical Group \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Paliperidone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Paliperidone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pimavanserin Tartrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Acadia Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Acadia Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Solriamfetol Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Axsome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Padagis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Padagis \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lumateperone Tosylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cellular Therapies \/ Not Applicable"},{"orgOrder":0,"company":"Medomie","sponsor":"Aytu BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Medomie","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Medomie \/ Aytu BioPharma","highestDevelopmentStatusID":"12","companyTruncated":"Medomie \/ Aytu BioPharma"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aspargo Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aspargo Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Harm Reduction Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harm Reduction Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Not Applicable"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Greater NY Chamber of Commerce","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mangoceuticals \/ Greater NY Chamber of Commerce","highestDevelopmentStatusID":"12","companyTruncated":"Mangoceuticals \/ Greater NY Chamber of Commerce"},{"orgOrder":0,"company":"Padagis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Padagis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Padagis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Padagis \/ Not Applicable"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mangoceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mangoceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Braeburn","sponsor":"Altruix","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Buprenorphine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braeburn","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"Braeburn \/ Altruix","highestDevelopmentStatusID":"12","companyTruncated":"Braeburn \/ Altruix"},{"orgOrder":0,"company":"J.B.Chemicals & Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Doxepin Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"J.B.Chemicals & Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"J.B.Chemicals & Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"J.B.Chemicals & Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Emergent BioSolutions","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Emergent BioSolutions \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emergent BioSolutions \/ Not Applicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sage Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sage Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mallinckrodt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Mallinckrodt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mallinckrodt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mallinckrodt Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Aspargo Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aspargo Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Difgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buprenoprhine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Difgen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film","sponsorNew":"Difgen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Difgen \/ Not Applicable"},{"orgOrder":0,"company":"Advanz Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Paliperidone Palmitate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Advanz Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Advanz Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Advanz Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Clobazam","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Pharmanovia","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Pharmanovia"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Aspargo Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aspargo Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Aripiprazole Monohydrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Otsuka Pharmaceutical \/ H. Lundbeck AS","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ H. Lundbeck AS"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Methylphenidate Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension, Extended Release","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharma Inc \/ Not Applicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Zuellig Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Luye Pharma \/ Zuellig Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Zuellig Pharma"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Distribution Solutions","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Luye Pharma \/ Distribution Solutions","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Distribution Solutions"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Cipla","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Luye Pharma \/ Cipla","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ Cipla"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"ICI Pakistan Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Luye Pharma \/ ICI Pakistan Limited","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ ICI Pakistan Limited"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"DCH Auriga","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Quetiapine Hemifumarate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate-Release Tablet","sponsorNew":"Luye Pharma \/ DCH Auriga","highestDevelopmentStatusID":"12","companyTruncated":"Luye Pharma \/ DCH Auriga"},{"orgOrder":0,"company":"Fabre-Kramer Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Gepirone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Fabre-Kramer Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Fabre-Kramer Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fabre-Kramer Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Unichem Laboratories Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Quetiapine Hemifumarate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Unichem Laboratories Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Unichem Laboratories Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Unichem Laboratories Limited \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Esketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Indivior","sponsor":"Alar Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Buprenorphine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Indivior","amount2":0.02,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Indivior \/ Alar Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Indivior \/ Alar Pharmaceuticals"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Perigon Pharmacy 360","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Amphetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tris Pharma Inc \/ Perigon Pharmacy 360","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharma Inc \/ Perigon Pharmacy 360"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Methylphenidate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating, Extended Release","sponsorNew":"Aytu BioPharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aytu BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Sage Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Zuranolone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Sage Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Sage Therapeutics"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Mangoceuticals \/ Boustead Securities","highestDevelopmentStatusID":"12","companyTruncated":"Mangoceuticals \/ Boustead Securities"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Olanzapine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Alkermes Plc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alkermes Plc \/ Not Applicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Akums Drugs & Pharmaceuticals Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tamsulosin","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Akums Drugs & Pharmaceuticals Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Akums Drugs & Pharmaceuticals Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akums Drugs & Pharmaceuticals Ltd \/ Not Applicable"},{"orgOrder":0,"company":"CTCBIO INC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"CTCBIO INC","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CTCBIO INC \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CTCBIO INC \/ Not Applicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Harm Reduction Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harm Reduction Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Zuellig Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Zuellig Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Zuellig Pharma"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Shilpa Medicare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Varenicline Tartrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Shilpa Medicare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Shilpa Medicare \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Shilpa Medicare \/ Not Applicable"},{"orgOrder":0,"company":"The University of New Mexico","sponsor":"Purdue Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Nalmefene Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"The University of New Mexico","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"The University of New Mexico \/ Purdue Pharma","highestDevelopmentStatusID":"12","companyTruncated":"The University of New Mexico \/ Purdue Pharma"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Aripiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Termination","leadProduct":"Dexmedetomidine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"BioXcel Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Film","sponsorNew":"BioXcel Therapeutics \/ BofA Securities","highestDevelopmentStatusID":"12","companyTruncated":"BioXcel Therapeutics \/ BofA Securities"},{"orgOrder":0,"company":"Difgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buprenorphine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Difgen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Difgen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Difgen \/ Not Applicable"},{"orgOrder":0,"company":"Harm Reduction Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Harm Reduction Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Harm Reduction Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Harm Reduction Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Brexpiprazole","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Otsuka Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Aspargo Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sildenafil Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Aspargo Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Aspargo Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Aspargo Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"Alora Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Methylphenidate Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Alora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Alora Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alora Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Iloperidone","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Vanda Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Eisai","sponsor":"CNX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Divestment","leadProduct":"Loxapine Succinate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Eisai","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eisai \/ CNX Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Eisai \/ CNX Therapeutics"},{"orgOrder":0,"company":"Emifarma","sponsor":"Mangoceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"MEXICO","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Tadalafil","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Emifarma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Emifarma \/ Mangoceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Emifarma \/ Mangoceuticals"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Lumateperone Tosylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0.5,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.57999999999999996,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ J.P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cellular Therapies \/ J.P. Morgan"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fluoxetine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Strides Pharma Science \/ Not Applicable"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Lumateperone Tosylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0.5,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.57999999999999996,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ J.P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cellular Therapies \/ J.P. Morgan"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Lumateperone Tosylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Intra-Cellular Therapies","amount2":0.57999999999999996,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0.57999999999999996,"dosageForm":"Capsule","sponsorNew":"Intra-Cellular Therapies \/ J.P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Intra-Cellular Therapies \/ J.P. Morgan"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Asenapine Maleate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Asenapine Maleate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Breckenridge Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Breckenridge Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Amneal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amneal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Purdue Pharma","sponsor":"MMCAP Infuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Buprenorphine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Purdue Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Purdue Pharma \/ MMCAP Infuse","highestDevelopmentStatusID":"12","companyTruncated":"Purdue Pharma \/ MMCAP Infuse"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Moksha8 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Viloxazine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Supernus Pharmaceuticals \/ Moksha8 Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Supernus Pharmaceuticals \/ Moksha8 Pharmaceuticals"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bupropion Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Tris Pharma Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Clonidine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Tris Pharma Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Tris Pharma Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tris Pharma Inc \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Dexmethylphenidate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Dextroamphetamine Saccharate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Mangoceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Clomiphene Citrate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Mangoceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Mangoceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Mangoceuticals \/ Not Applicable"},{"orgOrder":0,"company":"DMK Pharmaceuticals","sponsor":"ZMI Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Naloxone Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"DMK Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"DMK Pharmaceuticals \/ ZMI Pharma","highestDevelopmentStatusID":"12","companyTruncated":"DMK Pharmaceuticals \/ ZMI Pharma"},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Prochlorperazine Edisylate","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avenacy \/ Not Applicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Venlafaxine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Strides Pharma Science

                            India
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothStrides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.

                            Lead Product(s) : Fluoxetine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Strides Pharma Subsidiary Receives USFDA Approval for 60 mg Fluoxetine Tablets

                            Details : Fluoxetine hydrochloride, is an antidepressant of the SSRIs class. It is used for the treatment of major depressive disorder, obsessive–compulsive disorder, bulimia nervosa, etc.

                            Brand Name : Fluoxetine HCl-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 18, 2024

                            Lead Product(s) : Fluoxetine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Strides Pharma Science

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Granules India Limited

                            India
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

                            Lead Product(s) : Trazodone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Granules India Gains ANDA approval for Trazodone Tablets

                            Details : Desyrel-Generic (trazodone hydrochloride) is a selective serotonin reuptake inhibitor indicated for the treatment of patients with major depressive disorder.

                            Brand Name : Desyrel-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 09, 2024

                            Lead Product(s) : Trazodone Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Granules India

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Strides Pharma Science

                            India
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothStrides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.

                            Lead Product(s) : Fluoxetine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Strides Pharma Gets USFDA Nod for Antidepressant Medication

                            Details : Fluoxetine hydrochloride (Prozac) is an SSRI antidepressant used for major depressive disorder, OCD, bulimia, and panic disorder.

                            Brand Name : Prozac-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 08, 2024

                            Lead Product(s) : Fluoxetine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Strides Pharma Science

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sanofi

                            France
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Clobazam

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Pharmanovia

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Pharmanovia Acquires Global Central Nervous System (CNS) Portfolio from Sanofi

                            Details : Pharmanovia expands its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from Sanofi, including Frisium (clobazam), Gardenal (phenobarbital), Tercian (cyamemazine), Stemetil, Sentil, Urbanyl, Urbanil, Urbanol, Urbadan, N...

                            Brand Name : Frisium

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 18, 2023

                            Lead Product(s) : Clobazam

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Pharmanovia

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Granules India Limited

                            India
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

                            Lead Product(s) : Venlafaxine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Granules India Limited Received ANDA Approval for Venlafaxine ER Capsules

                            Details : Generic version of Venlafaxine HCl extended-release capsules has been approved which are indicated for the treatment of MDD, GAD, SAD and Panic Disorder (PD).

                            Brand Name : Effexor-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 19, 2023

                            Lead Product(s) : Venlafaxine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Granules India

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sanofi

                            France
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Levomepromazine Maleate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Neuraxpharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Neuraxpharm Announces Closing of Acquisition of Established Products from Sanofi

                            Details : The acquisition will strengthen Neuraxpharm's position as a leading company focused on CNS by including 2 product portfolios for CNS disorders, pain and vascular diseases. The CNS portfolio includes Nozinan (levomepromazine maleate), Tranxene, Tiapridal,...

                            Brand Name : Nozinan

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 01, 2023

                            Lead Product(s) : Levomepromazine Maleate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Neuraxpharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Granules India Limited

                            India
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

                            Lead Product(s) : Amphetamine,Dextroamphetamine Saccharate,Amphetamine Aspartate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Granules Pharmaceuticals Inc., Receives ANDA Approval for Amphetamine Mixed Salts ER Capsules

                            Details : Dextroamphetamine Sulfate is a non-catecholamine sympathomimetic amines with CNS stimulant activity. It is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extr...

                            Brand Name : Amphetamine-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 24, 2023

                            Lead Product(s) : Amphetamine,Dextroamphetamine Saccharate,Amphetamine Aspartate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Granules India

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AbbVie Inc

                            U.S.A
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cariprazine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            U.S. FDA Approves VRAYLAR® (cariprazine) as an Adjunctive Treatment for Major Depressive Disorder

                            Details : VRAYLAR (cariprazine) is an oral, once-daily atypical antipsychotic approved as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults (1.5 or 3 mg/day), for the treatment of depressive episodes associated with ...

                            Brand Name : Vraylar

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 16, 2022

                            Lead Product(s) : Cariprazine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sanofi

                            France
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Levomepromazine Maleate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Neuraxpharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Neuraxpharm to Increase Branded Business Through Upcoming Acquisition of Established Products from Sanofi

                            Details : Nozinan (levomepromazine) is a neuroleptic with indications in psychiatry and general medicine, particularly in terminal illness. Clinically it is more sedative and more potent than chlorpromazine in management of psychotic conditions and in relief of se...

                            Brand Name : Nozinan

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 12, 2022

                            Lead Product(s) : Levomepromazine Maleate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Neuraxpharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sanofi

                            France
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Tadalafil

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Update on Cialis® Rx-to-OTC Switch Actual Use Trial

                            Details : Cialis is a tablet having Tadalafil to treat erectile dysfunction, and symptoms of benign prostatic hyperplasia, and both ED and the signs and symptoms of BPH. Cialis is the only PDE-5 inhibitor treatment that offers men a choice fot treatment of erectil...

                            Brand Name : Cialis

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 30, 2022

                            Lead Product(s) : Tadalafil

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth